Geographic Area – Page 3

Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push

4 weeks ago talkbio0Tagged Billion, Biopharma, Fujifilm, Investments, Johnson and Johnson, Manufacturing, North Carolina, Surgical construction, U.S.

Johnson & Johnson; Fujifilm; manufacturing; North Carolina; $2 billion investment; biopharma; job creation; US manufacturing

Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance

4 weeks ago talkbio0Tagged Benefit, Clinical Trials, competition, Compounders, Direct-to-Consumer, eli lilly, Glucagon-Like Peptide 1, manager, Market, Nordisk, Obesity, Pharmaceutical Services, Wegovy, Zepbound

obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials

Eli Lilly Endorses Trump’s Goal by Raising Drug Prices Abroad to Align with U.S. Levels

1 month ago talkbio0Tagged Donald Trump, drug price, Eli, Eli Lilly, Europe, international pricing, Mounjaro, pharmaceutical tariffs, UK

Eli Lilly; drug prices; Donald Trump; international pricing; Mounjaro; U.K.; Europe; pharmaceutical tariffs; Project 2025

Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks

1 month ago talkbio0Tagged Drug Prescriptions, eli lilly, Free Nurse Program ', Glucagon-Like Peptide 1, Ken Paxton, kickback scheme, Medicaid fraud, Mounjaro, pharmaceutical litigation, Support Services Program, Texas, Zepbound

Eli Lilly; Texas Attorney General; kickback scheme; drug prescriptions; Mounjaro; Zepbound; GLP-1 drugs; Medicaid fraud; Free Nurse Program; Support Services Program; Ken Paxton; pharmaceutical litigation

AbbVie Invests $195 Million in New North Chicago API Manufacturing Site

1 month ago talkbio0Tagged AbbVie, alpha 1-antitrypsin, domestic production, expansion, Facility (object), Illinois (geographic location), Investments, Manufacturing, North Chicago, pharmaceutical manufacturing

AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production

Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires

1 month ago talkbio0Tagged Bariatric Surgery, biosimilars/generics, Capital Expenditures, China, competition, constraints, eli lilly, GLP-1 pipeline, Glucagon-Like Peptide 1, manufacturing capacity, Market, Medicare, Nordisk, Obesity, Policy, Risk, Wegovy, Zepbound

GLP-1; manufacturing capacity; Eli Lilly; Novo Nordisk; obesity drugs; Wegovy; Zepbound; capital expenditures; supply constraints; market competition; Medicare coverage; policy risk; biosimilars/generics; China GLP-1 pipeline; bariatric surgery

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

1 month ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop